期刊文献+

临床药物个体化治疗技术进展与展望 被引量:4

Progress and Prospect of Individualized Clinical Medication Techniques
原文传递
导出
摘要 近年来,个体化治疗已成为提高临床药物治疗有效性和安全性的关键策略。随着药物检测技术的不断进步以及药物基因组学技术在临床的应用,临床药物个体化治疗模式正在逐渐转变,检测方法和检测的药物品种也在不断增多。根据国内外相关文献和资料,对应用于临床药物个体化治疗的治疗药物监测和基因检测技术的研究与应用进展进行总结,并归纳了有望应用于个体化治疗的新技术,同时提出了目前临床个体化治疗模式仍存在的一些瓶颈问题及未来的发展方向。 In recent years,individualized therapy has become a key strategy to improve the efficacy and safety of clinical drug therapy.With the continuous development of drug detection technology and clinical application of pharmacogenomics,individualized clinical medication is gradually changing,with more detection methods and varieties of drugs.Based on domestic and foreign literature and information,this article reviews the research and application progress on therapeutic drug monitoring and gene testing technology used in individualized medication,and summarizes the potential new technologies expected to be applied to individualized therapy in the future,and at the same time,raises some bottleneck problems in the current clinical individualized treatment for the reference of future research.
作者 纪宏宇 于洋 蔡本志 JI Hongyu;YU Yang;CAI Benzhi(Department of Pharmacy,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)
出处 《药学进展》 CAS 2020年第6期404-410,共7页 Progress in Pharmaceutical Sciences
关键词 个体化治疗 治疗药物监测 基因检测 新技术 individualized treatment therapeutic drug monitoring gene testing new technology
  • 相关文献

参考文献1

二级参考文献8

  • 1Chao‐HungKuo,Sophie S.W.Wang,Wen‐HungHsu,Fu‐ChenKuo,Bi‐ChuangWeng,Chia‐JungLi,Ping‐IHsu,AngelaChen,Wen‐ChunHung,Yuan‐ChiehYang,Wen‐MingWang,Deng‐ChyangWu.Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy[J].Helicobacter.2010(4)
  • 2Chao-Hung Kuo,Fu-Chen Kuo,Huang-Ming Hu,Chung-Jung Liu,Sophie S. W. Wang,Yen-Hsu Chen,Ming-Chia Hsieh,Ming-Feng Hou,Deng-Chyang Wu,Ping-I Hsu.The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012[J].Gastroenterology Research and Practice.2012
  • 3Hao Li,Ling Meng,Fei Liu,Ji-Fu Wei,Yong-Qing Wang.H<sup>+</sup>/K<sup>+</sup>-ATPase inhibitors: a patent review[J].Expert Opinion on Therapeutic Patents.2013(1)
  • 4Kyung-Ah Seo,So-Jeong Lee,Kwon-Bok Kim,Soo Kyung Bae,Kwang-Hyeon Liu,Dong-Hyun Kim,Jae-Gook Shin.Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5[J].Xenobiotica.2012(3)
  • 5Dolores Serrano,Susana Torrado,Santiago Torrado-Santiago,Javier P. Gisbert.The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments[J].Current Drug Metabolism.2012(9)
  • 6Krisztina Hagym&aacute,si,Katalin M&uuml,llner,L&aacute,szl&oacute,Hersz&eacute,nyi,Zsolt Tulassay.Update on the pharmacogenomics of proton pump inhibitors[J].Pharmacogenomics.2011(6)
  • 7Choon‐SengQUA,JeetaMANIKAM,Khean‐LeeGOH.Efficacy of 1‐week proton pump inhibitor triple therapy as first‐line Helicobacter pylori eradication regime in Asian patients: Is it still effective 10 years on?[J].Journal of Digestive Diseases.2010(4)
  • 8Shaojun Shi,Ulrich Klotz.Proton pump inhibitors: an update of their clinical use and pharmacokinetics[J].European Journal of Clinical Pharmacology.2008(10)

共引文献35

同被引文献40

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部